Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Sexually Transmitted Diseases (STDs)








Legal Status of Expedited Partner Therapy (EPT)						Print
																Related Pages
										On This Page
			IntroductionExplanationLimitations
		
The information presented here is not legal advice, nor is it a comprehensive analysis of all the legal provisions that could implicate the legality of EPT in a given jurisdiction. The data and assessment are intended to be used as a tool to assist state and local health departments as they determine locally appropriate ways to control STDs. The information is not intended to be used for research purposes.
The “status as of” date on every state’s page reflects the most recent date that any law referenced on that page went into effect, even minor changes. To view information for each state, refer to the map or click on a state in the table below. This map is updated on an annual basis. It was last updated in November 2023. Summary Totals are here.
Map. Refer to table below.
This is a table caption for compliance. Ignore it please.
permissible EPT is permissible in 46 states:
potentially allowable EPT is potentially allowable in 4 states:
prohibited EPT is prohibited in 0 states:AlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOregonPennsylvaniaRhode IslandSouth CarolinaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingEPT is permissible in the District of Columbia.
EPT is permissible in the Commonwealth of the Northern Mariana Islands.
AlabamaKansasOklahomaSouth DakotaEPT is potentially allowable in Puerto Rico and Guam.Introduction
Assuring treatment of the sex partners of persons with sexually transmitted diseases (STD) has been a central component of prevention and control of bacterial STDs in the United States for decades. Traditional practices to inform, evaluate and treat sex partners of persons infected with STDs have relied upon patients or health care providers to notify partners of infected persons of their exposure to an STD. Initially developed to help control syphilis, partner management became widely recommended for gonorrhea, chlamydial infection and, most recently, human immunodeficiency virus (HIV) infection. However, for STDs other than syphilis, partner management based on provider referral is rarely assured, while patient referral has had only modest success in assuring partner treatment.
An alternative approach to assuring treatment of partners is expedited partner therapy (EPT). EPT is the delivery of medications or prescriptions by persons infected with an STD to their sex partners without clinical assessment of the partners. Clinicians (e.g., physicians, nurse practitioners, physician assistants, pharmacists, public health workers) provide patients with sufficient medications directly or via prescription for the patients and their partners. After evaluating multiple studies involving EPT, CDC concluded that EPT is a “useful option” to further partner treatment, particularly for male partners of women with chlamydia or gonorrhea. In August 2006, CDC recommended the practice of EPT for certain populations and specific conditions and CDC continues to recommend it in Sexually Transmitted Diseases Treatment Guidelines, 2010.
Throughout discussions of EPT, the legal status of the practice remained an area of uncertainty. To assist state and local STD programs in their efforts to implement EPT as an additional partner services tool, CDC collaborated with the Center for Law and the Public’s Health at Georgetown and Johns Hopkins Universities to assess the legal framework concerning EPT across all 50 states and other jurisdictions (the District of Columbia and Puerto Rico). The primary research objective was to conceptualize, frame, and identify legal provisions that implicate a clinician’s ability to provide a prescription for a patient’s sex partner, without prior evaluation of that partner, for purposes of treating an STD (specifically chlamydia or gonorrhea). The results of this research, with explanatory information for six key areas of inquiry and summary conclusions for each state are presented here.
The information presented here is not legal advice, nor is it a comprehensive analysis of all the legal provisions that could implicate the legality of EPT in a given jurisdiction. Rather, it provides a comparative snapshot of legal provisions that may highlight legislative, regulatory, judicial laws and policies concerning EPT based on currently available information. This snapshot is subject to change. Measuring the legal weight of non-binding legal sources, such as policy guidance documents or administrative decisions, must be done locally within the context of applicable statutes and regulations. The data and assessment are intended to be used as a tool to assist state and local health departments as they determine locally appropriate ways to control STDs. Assessment of local statutes was not undertaken, with the exception of the District of Columbia. Assessment of tribal laws for sovereign nations was also not undertaken.
** Top of Page
Explanation
Sections I – VII categorize key legal provisions implicating EPT as follows:
**Existing statutes/regulations that specifically address the ability of authorized health care providers to provide a prescription for a patient’s partner(s) without prior evaluation for certain STDs.** Section I includes statutory or regulatory provisions that specifically address whether a health care provider may provide a prescription for a patient’s partner without a prior evaluation or relationship with the partner. While these provisions may be limited in their application, they may effectually either authorize or prohibit EPT in specific circumstances. For example, a few states feature statutes or regulations that directly authorize some health care professionals to conduct EPT. These laws typically specify the STDs for which EPT is authorized as well as the health care professionals who are authorized to conduct EPT.
**Specific judicial decisions concerning EPT (or like practices).** Section II includes judicial decisions (case law) that implicate the legality of EPT or “like practices” (practices that are legally similar to EPT). Case law decisions are legally binding in their jurisdictions and set legal precedent for future decisions.
**Specific administrative opinions by the Attorney General or medical or pharmacy boards concerning EPT (or like practices).** Section III includes publicly-available decisions by state administrative bodies that discuss the legality of EPT or like practices. These decisions can include opinions of the state Attorney General, actions by medical disciplinary boards, advisory decisions or resolutions of medical or pharmacy boards, or general policy guidelines. Attorney General opinions are only binding on the party who sought the opinion, but the opinion may indicate how EPT may be regarded in the future.
**Laws that incorporate via reference guidelines as acceptable practices (including EPT).** Section V includes legal provisions that allow public health or clinical practices to be incorporated by reference through specific guidelines. Even if the current legal status of EPT in a jurisdiction is unclear, EPT could become legally permissible if a designated published guideline, agency, or official adopted EPT as an acceptable treatment method. The contents of these guidelines are incorporated by reference, which means they have the force of law in that jurisdiction. Legalization of EPT may thus be furthered by consulting with the organization that publishes the guideline or the agency official to recognize EPT as an acceptable treatment method for specific STDs provided such recommendation does not conflict with other legal provisions. The following abbreviations are used in this column of the table:
“CDC STD Treatment Guidelines” refers to *Sexually Transmitted Diseases Treatment Guidelines* published by CDC through its Morbidity and Mortality Weekly Reports (which explicitly supports the use of EPT for certain STDs and populations);
“APHA’s CCD Manual” refers to the *Control of Communicable Diseases in Man* published by the American Public Health Association; and
“AAP’s Red Book” refers to the *Red Book: Report of the Committee on Infectious Diseases* published by the American Academy of Pediatrics.
**Prescription requirements.** Section VI includes statutory or regulatory provisions that relate to prescription drug laws (other than for controlled substances) in each jurisdiction to the extent they may impact EPT. This may include:
laws that require prescription orders or labels to indicate identifying information about the person for whom the prescription is intended. If identifying information is not required, it may facilitate a physician writing a prescription for a patient to deliver to her partner without identifying the partner. While these laws do not necessarily implicate the legality of EPT, they affect how EPT may be implemented in practice. If patient-identifying information is required, a physician may not be legally permitted to provide a blank prescription or an “extra dose” for the patient to deliver to the partner. Instead, such a prescription may have to be made out in the partner’s name;
laws that concern the pharmacists’ need to verify a physician-patient relationship or that an individual has been examined by a physician prior to dispensing pharmaceutical products; or
laws that require a pharmacist to ensure that drugs are dispensed to an ultimate user of the prescription.
**Assessment of the legal status of EPT.** Section VII provides an assessment whether the various laws of the jurisdiction tend to support or reject the legality of EPT. One of three conclusions is indicated for each jurisdiction:permissible – **EPT is permissible** for certain practitioners and conditions;potentially allowable – **EPT is potentially allowable** subject to additional actions or policies (this may include specific interpretations of inconsistent or amorphous provisions, supporting policies consistent with legal authorization, or incorporation by reference into treatment guidelines); orprohibited – **EPT is likely prohibited**.Each of these initial conclusions is followed by brief comments providing some justification for the assessment.** Top of Page
Limitations
The information presented here is not legal advice, nor is it a comprehensive analysis of all the legal provisions that could implicate the legality of EPT in a given jurisdiction. Rather, it provides a comparative snapshot of legal provisions that may highlight legislative, regulatory, judicial laws and policies concerning EPT based on currently available information. This snapshot is subject to change. Measuring the legal weight of non-binding legal sources, such as policy guidance documents or administrative decisions, must be done locally within the context of applicable statutes and regulations. The data and assessment are intended to be used as a tool to assist state and local health departments as they determine locally appropriate ways to control STDs. The data and assessment are not intended to be used for research purposes; dates are provided for the most recent legal change regardless of whether it resulted in a changed status. Assessment of local statutes was not undertaken, with the exception of the District of Columbia. Assessment of tribal laws for sovereign nations was also not undertaken.
** Top of Page

Related Links
Expedited Partner Therapy Legal/Policy Toolkit
							
					
							Last Reviewed:  November 3, 2023						Source: 	Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeSexually Transmitted Diseases (STDs)
Diseases & Related Conditionsplus icon
Bacterial Vaginosis (BV)
Chlamydia
Gonorrhea
Hepatitis
Herpes
HIV/AIDS & STDs
Human Papillomavirus (HPV)
*Mycoplasma genitalium (Mgen)*
Pelvic Inflammatory Disease (PID)
STDs & Infertility
STDs during Pregnancyplus icon
Fact Sheet
Detailed Fact Sheet
Statistics
Treatment and Care
Archive
STD Risk and Oral Sex
Syphilis
Trichomoniasis
Other STDsplus icon
Archive
Life Stages and Populationsplus icon
Adolescents and Young Adultsplus icon
Adolescents and Technology
Adolescents and STDs Fact Sheet
Gay, Bisexual and Other MSMplus icon
Gay Men & STDs Fact Sheet
Preventionplus icon
Guidance During Disruption of STD Clinical Services
Just Diagnosed?
Which STD Tests Should I Get?
STD Lowdown Infographic
Program Management & Evaluation Toolsplus icon
Effective Interventions
Gap Assessment Toolkit
Internet Partner Services Toolkit
Outbreak Response Resourcesplus icon
Congenital Syphilis HAN Template
Disseminated Gonococcal Infection HAN Template
Gonorrhea with Reduced Susceptibility HAN Template
LGV HAN Template
Practical Use of Program Evaluation
Program Operations Guidelines
S.P.A.C.E. Monkey
STD Informatics and Surveillance
Projects & Initiativesplus icon
EHE: Scaling Up HIV Prevention Services in STD Specialty Clinics
Gonococcal Isolate Surveillance Project (GISP)
Disease Interventionplus icon
Disease Intervention Training Centers
National Disease Intervention Specialists (DIS) Recognition Day
Resources
National Network of Prevention Training Centers (NNPTC)
STD PCHDplus icon
CDC DIS Workforce Development Funding
Guidance
STD Health Equityplus icon
Community Approaches to Reducing STDs
Sexual Health Cultural Competence Resources
Archive
STD Surveillance Network (SSuN)
Archive
Statisticsplus icon
STI Surveillance 2022
Gonococcal Isolate Surveillance Project Profiles
Syphilis Supplement
STI Prevalence, Incidence, and Cost Estimatesplus icon
At A Glance
Social Media Materials
Indian Health Service Reports
Social Media & Moreplus icon
The State of STIs Infographicplus icon
Customizable
HTML version
SDSB Contacts
Archive
Tools & Materialsplus icon
Brochuresplus icon
The Facts Brochures
Fact Sheets
Infographics
Provider Pocket Guides
Social Media Resources
Videos and Podcastsplus icon
Let’s Talk About Sexual Health
Safe in the City
Webinars
Widgets
Archive
Trainingplus icon
STD Prevention Courses
SASSI – SAS Training
STD Clinical Slidesplus icon
STD Clinical Slides
STD Picture Cardsplus icon
STD Picture Cards
Treatment and Screeningplus icon
Availability of STI Testing & Treatment Products
Duty to Warn
Expedited Partner Therapyplus icon
Gonorrhea Guidance
Legal Status of EPT
Legal/Policy Toolkit
Laboratory Information
Prenatal Syphilis Screening Laws
STD QCSplus icon
STD QCS Webinar Questions
STI Treatment Guidelines, 2021
A Guide to Taking a Sexual History
Additional Resources
Archive
About the Division of STD Preventionplus icon
STI Funding at Workplus icon
STI Prevention Success Stories
Success Bulletins
Strategic Plan 2022-2026
Fundingplus icon
Funding Archive
Archive The dynamic nature of EPT and its associated legal and policy implications means that information may change, and there may be links on these web pages that no longer work properly. We welcome your suggestions for making this tool more useful to you and invite your assistance in pointing out inconsistencies or non-working links. We also welcome updates from you about progress in your state or local area. For comments, feedback and updates, please contact CDC-INFO: https://www.cdc.gov/cdc-info/. Social_round_twitterSTD on Twitter
Social_round_facebookSTD on Facebook


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue